spacer
home > ebr > summer 2004 > panacea in the pipeline - promising drug development efforts offer hope to cancer patients
PUBLICATIONS
European Biopharmaceutical Review

Panacea in the Pipeline - Promising Drug Development Efforts Offer Hope to Cancer Patients

The fight against cancer is one of the most arduously fought battles that the global pharmaceutical industry is engaged in. Cancer therapeutics R&D has evolved over the years in its attempt to find the cure for cancer in its many avatars. We might not know all about cancer and how to conquer it even today, but our knowledge about cancer and the therapeutic interventions is significant, given what it was even as recently as a decade ago. Basic and applied research in oncology has evolved by leaps and bounds, and there are more players with increasingly new approaches and a considerably growing number of pipeline drugs that are trying to tackle some of the biggest killer cancer types. Newer technologies and novel techniques have been deployed by the industry in this pitched battle; emerging and nascent disciplines like biotechnology and nanotechnology hold a lot of promise. This article takes a look at some of these efforts to understand what is in store for millions of hopeful cancer patients across the world.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Rajaram Sankaran, Industry Analyst with Frost & Sullivan's Technical Insights Division

Rajaram Sankaran is an Industry Analyst for Frost and Sullivan's Technical Insights Division, tracking advances in the pharmaceuticals, biotechnology, medical devices and diagnostic imaging industries. He is currently working on a research service entitled 'Nanomedicine - Global Developments and Growth Opportunities'. Previous experience includes assignments for Procter and Gamble, Roche Molecular Diagnostic Systems and two of India's top 10 pharmaceutical companies, Lupin Laboratories and Ranbaxy Laboratories. Rajaram graduated from Nagarjuna University in Physical Sciences and completed postgraduate studies in Management at IIFM, Bhopal.

spacer
Rajaram Sankaran
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Breakthrough in the global battle against polio: AJ Vaccines granted WHO prequalification for new polio vaccine

Despite ongoing concerted efforts to eradicate polio, it appears to be on the rise again with more cases registered in 2019 than 2018. Looking ahead, AJ Vaccines’ dose sparing technology provides a significant opportunity to expand supply, with the potential to deliver up to 100 million doses over the five-year period 2020-2024 to help meet the currently unmet global demand for inactivated polio vaccines.
More info >>

White Papers

Crunch Time: The Impact of Serialisation Requirements on Packaging Operations

PCI Pharma Services

The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement